“Thrive” Obtains FDA Approval As A New Smoking Cessation Drug
Date: 25th June 2007
According to sources, the FDA (Food and Drugs Administration) has recently approved Thrive; a new quit smoking medication manufactured by Parsippany, NJ-based Novartis Consumer Health and further revelation makes it clear that FDA has approved this new smoking cessation medication a year after the drug authority granted approval to Pfizer manufactured chantix for smoking cessation.
According to spokesmen from the manufacturing company Novartis Consumer Health, this new medicine is a mint-flavored nicotine-replacement gum and is capable of inducing quit smoking in people just within a period of 12 weeks. The company is distributing Thrive in 2-mg and 4-mg dosages among which the 2 mg dosage is for people who smoke less than 25 cigarettes on a daily basis and the 4 mg dosage is for people who have the habit of smoking 25 or more cigarettes regularly.
Regarding the functioning process of Thrive, the new nicotine-replacement gum, it is known that the drug releases a little amount of nicotine in the blood and reduces craving as well as other smoking withdrawal symptoms.
The cost of the medicine has not been divulged and revelations from Novartis Consumer Health make it clear that when Thrive would be available for sale in 2007, Thrive user's guide and audio CD would be provided to the customers along with the drug. Moreover, the company is also planning to assist smokers in quit smoking counseling via the toll-free line 866.384.3011. |
